| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Non-secretion of ABO blood group antigens as a host susceptibility factor in the spondyloarthropathies.
|
Br Med J (Clin Res Ed)
|
1987
|
1.91
|
|
2
|
Bronchodilatation after inhalation of the antihistamine clemastine.
|
Thorax
|
1978
|
1.76
|
|
3
|
Health economics as an aspect of health outcome: basic principles and application in rheumatoid arthritis.
|
Br J Rheumatol
|
1995
|
1.43
|
|
4
|
Measuring health status in British patients with rheumatoid arthritis: reliability, validity and responsiveness of the short form 36-item health survey (SF-36).
|
Br J Rheumatol
|
1998
|
1.38
|
|
5
|
Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation.
|
BMJ
|
1998
|
1.35
|
|
6
|
Depression of lymphocyte responses after surgical trauma.
|
Br J Exp Pathol
|
1973
|
1.29
|
|
7
|
Translocation of protein kinase C to a Triton-insoluble sub-cellular compartment induced by the lipophilic gold compound auranofin.
|
Biochem Pharmacol
|
1988
|
1.06
|
|
8
|
Uptake of chloroquine and hydroxychloroquine by human blood leucocytes in vitro: relation to cellular concentrations during antirheumatic therapy.
|
Ann Rheum Dis
|
1987
|
1.02
|
|
9
|
Modulation by phorbol myristate acetate of arachidonic acid release and leukotriene synthesis by human polymorphonuclear leukocytes stimulated with A23187.
|
Biochem Biophys Res Commun
|
1986
|
1.00
|
|
10
|
Zinc increases phorbol ester receptors in intact B-cells, neutrophil polymorphs and platelets.
|
FEBS Lett
|
1989
|
0.98
|
|
11
|
Molecular basis of activation and regulation of the phagocyte respiratory burst.
|
Ann Rheum Dis
|
1987
|
0.96
|
|
12
|
Evidence for defect of complement-mediated phagocytosis by monocytes from patients with rheumatoid arthritis and cutaneous vasculitis.
|
Br Med J (Clin Res Ed)
|
1981
|
0.94
|
|
13
|
Is chronic renal failure a risk factor for the development of erosive osteoarthritis?
|
Ann Rheum Dis
|
1989
|
0.93
|
|
14
|
Coxsackie B infection and arthritis.
|
Br Med J (Clin Res Ed)
|
1983
|
0.93
|
|
15
|
Differential effects of mepacrine, chloroquine and hydroxychloroquine on superoxide anion generation, phospholipid methylation and arachidonic acid release by human blood monocytes.
|
Biochem Pharmacol
|
1986
|
0.92
|
|
16
|
A pilot study of the economic cost and clinical outcome of day patient vs inpatient management of active rheumatoid arthritis.
|
Br J Rheumatol
|
1994
|
0.86
|
|
17
|
Functional defects of monocyte C3b receptor-mediated phagocytosis in rheumatoid arthritis (RA): evidence for an association with the appearance of a circulating population of non-specific esterase-negative mononuclear phagocytes.
|
Ann Rheum Dis
|
1983
|
0.85
|
|
18
|
Evidence for intrinsic cellular defects of 'complement' receptor-mediated phagocytosis in patients with systemic lupus erythematosus (SLE).
|
Clin Exp Immunol
|
1984
|
0.84
|
|
19
|
Studies of the effect of D-penicillamine and sodium aurothiomalate therapy on superoxide anion production by monocytes from patients with rheumatoid arthritis: evidence for in vivo stimulation of monocytes.
|
Ann Rheum Dis
|
1986
|
0.84
|
|
20
|
Wegener's granulomatosis complicated by diabetes insipidus.
|
Ann Rheum Dis
|
1983
|
0.84
|
|
21
|
Inhibition of epidermal growth factor binding to HeLa cells by auranofin.
|
Biochem Pharmacol
|
1987
|
0.83
|
|
22
|
Calcium ionophore A23187 enhances human neutrophil superoxide release, stimulated by phorbol dibutyrate, by converting phorbol ester receptors from a low- to high-affinity state.
|
FEBS Lett
|
1987
|
0.83
|
|
23
|
Medically unexplained symptoms in patients referred to a specialist rheumatology service: prevalence and associations.
|
Rheumatology (Oxford)
|
2003
|
0.82
|
|
24
|
Quantifying the burden of emotional ill-health amongst patients referred to a specialist rheumatology service.
|
Rheumatology (Oxford)
|
2003
|
0.81
|
|
25
|
Monocyte superoxide anion production in rheumatoid arthritis: preliminary evidence for enhanced rates of superoxide anion production by monocytes from patients receiving penicillamine, sodium aurothiomalate and corticosteroids.
|
Ann Rheum Dis
|
1984
|
0.81
|
|
26
|
An audit of methotrexate and folic acid for rheumatoid arthritis. Experience from a teaching centre.
|
Br J Rheumatol
|
1995
|
0.81
|
|
27
|
Cervical spine surgery in patients with rheumatoid arthritis: an appraisal.
|
Ann Rheum Dis
|
1996
|
0.81
|
|
28
|
Auranofin stimulates LTA hydrolase and inhibits 5-lipoxygenase/LTA synthase activity of isolated human neutrophils.
|
Biochem Pharmacol
|
1990
|
0.81
|
|
29
|
IgG (kappa) paraproteinaemia and arthritis.
|
Br J Rheumatol
|
1987
|
0.80
|
|
30
|
An evaluation of the Health Assessment Questionnaire (HAQ) in a long-term longitudinal follow-up of disability in rheumatoid arthritis.
|
Br J Rheumatol
|
1994
|
0.80
|
|
31
|
Inhibition of protein kinase C activity by the antirheumatic drug auranofin.
|
Biochem Pharmacol
|
1989
|
0.78
|
|
32
|
Effects of piroxicam on superoxide generation, phospholipid methylation and leukotriene production by human blood mononuclear cells.
|
J Rheumatol
|
1987
|
0.78
|
|
33
|
Transient presence in serum of an atypical alkaline phosphatase.
|
Clin Chim Acta
|
1976
|
0.78
|
|
34
|
Enhancement of protein kinase C-mediated EGF receptor phosphorylation by auranofin.
|
Scand J Rheumatol
|
1988
|
0.78
|
|
35
|
Premature development of erosive osteoarthritis of hands in patients with chronic renal failure.
|
Ann Rheum Dis
|
1990
|
0.77
|
|
36
|
Sjögren's syndrome, vasculitis, and cryoglobulinaemia associated with a monoclonal IgM (kappa) paraprotein with rheumatoid factor activity.
|
Ann Rheum Dis
|
1987
|
0.77
|
|
37
|
Re: Quality of life measures.
|
Br J Rheumatol
|
1997
|
0.77
|
|
38
|
Auranofin increases the affinity of phorbol dibutyrate receptors in chronic lymphocytic leukemia cells (B cells).
|
J Immunol
|
1987
|
0.76
|
|
39
|
Reactive arthritis--infectious agents and genetic susceptibility in the pathogenesis of sero-negative arthritis.
|
Scott Med J
|
1983
|
0.76
|
|
40
|
Does economic evaluation have anything to offer the rheumatologist?
|
Rheumatology (Oxford)
|
1999
|
0.76
|
|
41
|
Screening for antimalarial maculopathy in rheumatology clinics.
|
Br Med J (Clin Res Ed)
|
1985
|
0.75
|
|
42
|
Diagnostic criteria for work-related upper limb disorders.
|
Br J Rheumatol
|
1997
|
0.75
|
|
43
|
Sclerosing injections in patients with chronic low back pain.
|
Rheumatology (Oxford)
|
2000
|
0.75
|
|
44
|
Combination therapy in rheumatoid arthritis.
|
Rheumatology (Oxford)
|
1999
|
0.75
|
|
45
|
Re: Measuring outcomes in rheumatoid arthritis--which measures are suitable for routine use?
|
Br J Rheumatol
|
1997
|
0.75
|
|
46
|
Vasculitis, Raynaud's phenomenon and polyarthritis associated with gemfibrozil therapy.
|
Br J Rheumatol
|
1993
|
0.75
|
|
47
|
Modulation of human neutrophil LTA hydrolase activity by phorbol myristate acetate.
|
Biochem Biophys Res Commun
|
1987
|
0.75
|
|
48
|
Destructive spondylarthropathy and chronic renal failure.
|
Arthritis Rheum
|
1988
|
0.75
|
|
49
|
Phorbol 12-myristate 13-acetate, A23187 and L-adrenaline inhibit phospholipid methylation in human monocytes and lymphocytes. Inhibition is independent of oxyradical production and phospholipid hydrolysis.
|
Free Radic Biol Med
|
1990
|
0.75
|
|
50
|
Effect of corticosteroid therapy on blood monocyte superoxide generation in rheumatoid arthritis: studies in vitro and ex vivo.
|
Br J Rheumatol
|
1986
|
0.75
|
|
51
|
Auranofin enhances phosphorylation of putative substrates of protein kinase C in human platelets.
|
Biochem Pharmacol
|
1988
|
0.75
|
|
52
|
Calcium ionophore A23187 primes human B-cells for activation by phorbol dibutyrate by converting receptors for phorbol dibutyrate from a low to high affinity state.
|
Biochem Biophys Res Commun
|
1986
|
0.75
|
|
53
|
The effects of anti-inflammatory and anti-rheumatic drugs on phagocyte cell function.
|
Agents Actions Suppl
|
1988
|
0.75
|
|
54
|
Erdheim-Chester disease associated with hydrocalycosis and arthropathy.
|
Arthritis Rheum
|
1988
|
0.75
|